Venocare, Inc. appears in FDA device records as an applicant for premarket notification clearances covering the Ruby Intravascular Catheter. The supplied filings show two substantially equivalent decisions for the same trade name and regulation, dated May 16, 2025 and September 2, 2026. The company's website presents Ruby as a soft-tip guided peripheral intravenous catheter and also lists a separate Navi line. The record set reviewed here contains one linked 510(k) record, a snapshot of supplied filings rather than a measure of total portfolio, sales or safety performance. [1][2][6][8][4]
Documented clearances and filing dates
The MedtechLedger snapshot lists one linked 510(k) record for Venocare, Inc.: K260432 for the Ruby Intravascular Catheter, received February 11, 2026, with a September 2, 2026 decision of substantially equivalent. The collection's decision counts show one SESE decision, and the explicitly smaller record sample shows the same single SESE entry, so the two denominators are not interchangeable. A separate FDA clearance letter in the sources covers K243105, dated May 16, 2025, for the same trade name and regulation. [1][2][6]
The K260432 clearance letter identifies the device as a Class II intravascular catheter under 21 CFR 880.5200, product code FOZ, and carries a later correspondence date of July 31, 2026 with receipt on August 3, 2026. The K243105 letter states the same regulation number, regulation name, class and product code. Both letters describe the device as substantially equivalent. [2][6]
The K243105 premarket notification page records a September 30, 2024 receipt date, a May 16, 2025 decision date, a traditional review type, no third-party review and no combination product status. It lists Daniel & Daniel, LLC as correspondent with Mark Smutka as contact. The K260432 letter is addressed to Ivenette Guzman as Vice-President of Quality Assurance & Regulatory Affairs at a Doral, Florida address. [8][2]
Product identity and stated design features
FDA records classify the Ruby Intravascular Catheter within the device classification Catheter, Intravascular, Therapeutic, Short-Term Less Than 30 Days, with a General Hospital medical specialty. The K260432 letter describes the means of insertion as percutaneous over a catheter guiding element and the insertion site as peripheral, matching the predicate on both points. [3][2]
Venocare's Ruby page calls the device the only soft-tip guided PIVC and states that its needle and guide element are engineered to support vein longevity, catheter placement and patient comfort. The same page says the guiding element is designed to increase therapy administration success. These are the company's own product descriptions, not independently verified outcomes. [4]
The company's features page lists a low-profile bevel tip needle described as patent pending, soft wings intended to reduce device pressure on skin and provide greater surface area for securement, a blood control valve, and an ergonomic design allowing guide wire advancement with haptic feedback. The page states the blood control valve decreases clinician exposure to bloodborne pathogens. [7]
Company identity and published product lines
The FDA applicant name across the supplied filings is Venocare, Inc. The K243105 notification page lists a Doral, Florida address on NW 36th Street, while the K260432 letter and notification page list a Doral address on NW 87th Avenue. Filing addresses are correspondence locations in these records and are not treated here as a verified headquarters. [8][3][2]
Venocare's website describes the company as working on vascular access devices and lists Ruby and Navi as separate product lines, each with overview and features pages. The site's home page presents Ruby imagery and a general statement about transforming patient care with vascular access devices. No parent company, brand owner or corporate ownership structure is verified in the public documents. [5][4]
